Asset Management Ventures

Asset Management Ventures has been writing seed and Series A checks out of Palo Alto for longer than most of its peers have existed. The firm, often referred to simply as AMV, was a quiet fixture of Sand Hill Road’s early-stage ecosystem long before digital health was a category, and it has spent the intervening decades steadily building a portfolio across information technology, life sciences, and the parts of healthcare where software and clinical service collide. AMV is not a fund that markets itself heavily, and it does not need to: the firm’s history of partnering with technical and physician founders at the earliest stages is well known to repeat-founder networks in the Bay Area. For physician entrepreneurs who want a low-noise, high-trust early backer with deep healthcare pattern recognition, AMV is one of the more durable options on the West Coast.

The stated thesis is broad: AMV invests at the seed and Series A stages across information technology, life sciences, and healthcare, with healthcare interests spanning digital health, health IT and healthcare software, wellness and consumer health, and care delivery and tech-enabled services. Within healthcare, the firm gravitates toward companies that sit at the intersection of software and clinical workflow rather than pure-play therapeutics or device. They tend to back tech-enabled service businesses where a software platform is the lever that makes a labor-intensive clinical category scalable, and health IT companies that sell into provider organizations or risk-bearing entities. The firm is not AI-thesis-led, though they have invested in AI-adjacent infrastructure and applications where the underlying business is healthcare-relevant. Founders should expect a partner who is comfortable being early, comfortable with technical complexity, and comfortable letting a thesis develop across multiple rounds.

AMV’s portfolio history is one of the longer ones in Silicon Valley healthcare investing, and the firm has historically participated in early rounds for companies that later became names in digital health, healthcare software, and tech-enabled care delivery. The pattern across their healthcare investments is a preference for companies with technical defensibility, founders with domain credibility, and a clear path from early adopter customers to broader institutional sales. AMV tends to avoid pure consumer plays without a clinical or institutional layer, and they are skeptical of healthcare businesses whose entire moat is brand. They also tend to avoid extremely capital-intensive therapeutics where a pure-play biotech specialist would be the obvious lead.

Check sizes are in the $1 million to $5 million range, consistent with a seed and Series A practice that takes meaningful early ownership but does not lead the largest priced rounds in the market. The firm is comfortable both leading and co-investing, and they will often share rounds with sector-specialist seed funds and larger generalists who pile on at Series A. Founders raising a $3 million to $6 million seed will find AMV a credible lead. Founders raising a $15 million Series A typically bring AMV in as a continuation investor or as a thesis-aligned co-investor alongside a larger lead. The firm’s reserve discipline is more conservative than the typical multi-stage fund; they will not write the largest check in your Series C, but they will reliably support good companies through the rounds they participate in.

The team at AMV has been known for partner stability over the years, with senior investors who have spent the bulk of their careers in early-stage Silicon Valley investing. The firm is not partner-rotational; the people you meet at first pitch are the people who will sit on your board and run your reference calls. Decision-making is consensus-led and partner-driven, and the diligence process tends to be thorough rather than fast. References are typically pulled from technical and clinical experts in the firm’s network, including operating advisors with backgrounds in healthcare software and provider organizations.

The most reliable path into AMV is a warm introduction from a portfolio founder or from a Bay Area healthcare operator who has worked with the firm. AMV is well known to the senior partners at firms like NEA, Venrock, and a handful of other Sand Hill staples, and introductions from those funds carry weight. Cold outreach is read, particularly when it is technically substantive, but the firm’s preferred entry point is a founder reference. Communication after first contact tends to be direct and unhurried; expect a partner to ask sharp questions and then go quiet for a week while diligence runs.

Approach AMV when you are a technical or physician founder building software-enabled healthcare infrastructure, and when you want a partner who will sit with you through the slow parts of the early stage. Do not approach when you need a brand-forward consumer investor, when you are raising a therapeutics round and need pharma syndicate access, or when you are running a fast process and need a decision in days rather than weeks. AMV is a steady, technically rigorous early backer for healthcare software founders who value continuity over noise.